Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LRRK2


Brief Information

Name:Leucine-rich repeat serine/threonine-protein kinase 2
Target Synonym:PARK8,LRRK2,Leucine Rich Repeat Kinase 2,Leucine-Rich Repeat Serine/Threonine-Protein Kinase 2,Parkinson Disease (Autosomal Dominant) 8,Augmented In Rheumatoid Arthritis 17,Dardarin,AURA17,RIPK7,ROCO2,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2,DKFZp434H2111,FLJ45829
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
LK2-H5243 Human Human LRRK2 Protein, His Tag
LK2-H5245 Human Human LRRK2 (G2019S) Protein, His Tag
ACRO Quality

Synonym Name

PARK8,Leu-rich repeat/LRR-containing protein kinase 2,Dardarin


Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin and PARK8, is a kinase enzyme that in humans is encoded by the LRRK2 gene. LRRK2 is a member of the leucine-rich repeat kinase family, which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, autophagy, and vesicle trafficking. Mutations in the LRRK2 gene causes one of the most common monogenic forms of Parkinson disease (PD) . Also, several polymorphic variants in LRRK2 also modulate risk of sporadic PD.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VRN-01 VRN-01 Phase 1 Clinical Voronoi Pancreatic Neoplasms; Breast Neoplasms Details
DNL-201 DNL-201 F. Hoffmann-La Roche Ltd Details
BIIB-094 BIIB-094; ION-859; IONIS-BIIB7Rx Phase 2 Clinical Biogen Inc Parkinson Disease Details
WXWH0226 WXWH0226; WXWH-0226 Phase 1 Clinical Guizhou Inochini Technology Co Ltd, Wuxi Apptec Co Ltd Parkinson Disease Details
NEU-723 NEU-723 Phase 1 Clinical Parkinson Disease Details
DNL-151 BIIB-122; DNL-151 Phase 3 Clinical F. Hoffmann-La Roche Ltd, Biogen Inc Parkinson Disease Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message